IN2005KO00272A - - Google Patents
Download PDFInfo
- Publication number
- IN2005KO00272A IN2005KO00272A IN272KO2005A IN2005KO00272A IN 2005KO00272 A IN2005KO00272 A IN 2005KO00272A IN 272KO2005 A IN272KO2005 A IN 272KO2005A IN 2005KO00272 A IN2005KO00272 A IN 2005KO00272A
- Authority
- IN
- India
- Prior art keywords
- carbon atoms
- halogen
- alkyl
- formula
- alkenyl
- Prior art date
Links
- 125000004432 carbon atom Chemical group C* 0.000 abstract 24
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000004950 trifluoroalkyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33666301P | 2001-12-05 | 2001-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2005KO00272A true IN2005KO00272A (hu) | 2015-08-07 |
Family
ID=23317104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN272KO2005 IN2005KO00272A (hu) | 2001-12-05 | 2005-04-04 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US6794403B2 (hu) |
| EP (2) | EP1982713A3 (hu) |
| JP (2) | JP4689960B2 (hu) |
| KR (1) | KR20050044717A (hu) |
| CN (2) | CN101423500A (hu) |
| AR (1) | AR037745A1 (hu) |
| AU (2) | AU2002353014A1 (hu) |
| BR (1) | BR0214767A (hu) |
| CA (1) | CA2467517C (hu) |
| CO (1) | CO5580830A2 (hu) |
| EC (1) | ECSP045133A (hu) |
| HU (1) | HUP0500010A2 (hu) |
| IL (1) | IL162256A0 (hu) |
| IN (1) | IN2005KO00272A (hu) |
| MX (1) | MXPA04005306A (hu) |
| NO (1) | NO20042811L (hu) |
| NZ (1) | NZ560878A (hu) |
| PL (1) | PL370771A1 (hu) |
| RU (2) | RU2330847C2 (hu) |
| SG (1) | SG165987A1 (hu) |
| TW (1) | TW200304822A (hu) |
| UA (1) | UA83620C2 (hu) |
| WO (1) | WO2003050095A1 (hu) |
| ZA (1) | ZA200405249B (hu) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL205733B1 (pl) | 2001-11-19 | 2010-05-31 | Lilly Co Eli | Podstawiona pochodna benzopiranu, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| TW200409759A (en) | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
| PT1988397E (pt) | 2002-12-19 | 2011-12-02 | Scripps Research Inst | Composições e utilizações para estabilização da transtirretina e inibição do enrolamento |
| PT1626974E (pt) * | 2003-04-21 | 2008-11-14 | Lilly Co Eli | Benzopiranos substituídos como agonistas selectivos do receptor beta de estrogénio |
| TW200500065A (en) * | 2003-05-21 | 2005-01-01 | Wyeth Corp | Antiarthritic combinations |
| WO2005113523A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| US20060004087A1 (en) * | 2004-07-01 | 2006-01-05 | Wyeth | Tetracyclic compounds as estrogen ligands |
| CN101044126A (zh) * | 2004-08-26 | 2007-09-26 | 惠氏公司 | 作为雌激素药物的前药取代的苯并唑化合物 |
| US7585871B2 (en) * | 2004-09-02 | 2009-09-08 | Wyeth | Phenanthridine carbonyl phenols |
| AU2005282554A1 (en) | 2004-09-07 | 2006-03-16 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
| EP1819321A2 (en) * | 2004-12-02 | 2007-08-22 | Wyeth, A Corporation of the State of Delaware | Formulations of substituted benzoxazoles |
| US20060121111A1 (en) * | 2004-12-02 | 2006-06-08 | Wyeth | Formulations of substituted benzoxazoles |
| JP2008521919A (ja) * | 2004-12-02 | 2008-06-26 | ワイス | 置換ベンゾオキサゾールの製剤 |
| CA2590258A1 (en) * | 2004-12-17 | 2006-06-22 | Wyeth | Novel uses for estrogen beta agonists |
| EP1853578A1 (en) * | 2005-02-15 | 2007-11-14 | Eli Lilly And Company | Substituted tetralins as selective estrogen receptor-beta agonists |
| EP1848427A1 (en) * | 2005-02-16 | 2007-10-31 | Wyeth a Corporation of the State of Delaware | Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis |
| EP1856068A1 (en) | 2005-03-07 | 2007-11-21 | Wyeth, A Corporation of the State of Delaware | Process for the purification of substituted benzoxazole compounds |
| US20060199852A1 (en) * | 2005-03-07 | 2006-09-07 | Wyeth | Process for the preparation of substituted benzoxazole compounds |
| US7683182B2 (en) * | 2005-03-08 | 2010-03-23 | Wyeth Llc | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| JP5042215B2 (ja) | 2005-05-26 | 2012-10-03 | ニューロン システムズ， インコーポレイテッド | 網膜疾患を処置するための組成物および方法 |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| TW200800177A (en) * | 2006-02-14 | 2008-01-01 | Wyeth Corp | Aqueous pharmaceutical formulations of ERβ selective ligands |
| PE20080116A1 (es) * | 2006-03-06 | 2008-02-25 | Wyeth Corp | Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol |
| AR059742A1 (es) * | 2006-03-06 | 2008-04-23 | Wyeth Corp | Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol |
| US20070207201A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Liquid and Semi-Solid Pharmaceutical Formulations and Processes |
| US20070208067A1 (en) * | 2006-03-06 | 2007-09-06 | Wyeth | Tablet Formulations and Processes |
| JP4986485B2 (ja) * | 2006-03-28 | 2012-07-25 | 株式会社Ａｄｅｋａ | エポキシ樹脂硬化性組成物 |
| EP2074223A4 (en) * | 2006-09-15 | 2010-03-10 | Foldrx Pharmaceuticals Inc | TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS |
| US20080175900A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080146630A1 (en) * | 2006-11-21 | 2008-06-19 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080176914A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20090239920A1 (en) * | 2006-11-21 | 2009-09-24 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| WO2008064217A2 (en) * | 2006-11-21 | 2008-05-29 | Wyeth | Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof |
| US20080175901A1 (en) * | 2006-11-21 | 2008-07-24 | Wyeth | Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080139633A1 (en) * | 2006-11-21 | 2008-06-12 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080241234A1 (en) * | 2006-11-21 | 2008-10-02 | Wyeth | Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20080132554A1 (en) * | 2006-11-21 | 2008-06-05 | Wyeth | Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2008091555A2 (en) | 2007-01-22 | 2008-07-31 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| PE20081699A1 (es) * | 2007-01-31 | 2008-12-31 | Wyeth Corp | DERIVADOS DE HIDROXIFENILO COMO LIGANDOS SELECTIVOS DE ERß |
| US20080194533A1 (en) * | 2007-02-09 | 2008-08-14 | Wyeth | Process for selective sulfation of aromatic hydroxyl groups |
| US20080262009A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts |
| US20080275073A1 (en) * | 2007-04-20 | 2008-11-06 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as pharmaceutically acceptable salts |
| US20080262010A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts |
| US20080262008A1 (en) * | 2007-04-20 | 2008-10-23 | Wyeth | Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts |
| WO2009009417A2 (en) * | 2007-07-06 | 2009-01-15 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| EP2250180A1 (en) * | 2008-02-08 | 2010-11-17 | Wyeth LLC | Phosphate derivatives of substituted benzoxazoles |
| WO2010036908A1 (en) * | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Use of benzoxazole compounds in the treatment of malaria |
| EP2350032B1 (en) * | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| WO2010083199A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| WO2011014516A1 (en) | 2009-07-28 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Estrogen antagonists as treatments for sclerosing disorders |
| CA2812438A1 (en) * | 2010-10-01 | 2012-04-05 | Indiana University Research And Technology Corporation | Treatment of symptoms associated with menopause |
| WO2012118935A1 (en) * | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| JP5869677B2 (ja) | 2011-09-16 | 2016-02-24 | ファイザー・インク | トランスサイレチン解離阻害剤の固体形態 |
| EP2938601B1 (en) * | 2012-12-27 | 2018-05-16 | Sumitomo Chemical Company Limited | Fused oxazole compounds and use thereof for pest control |
| KR102243169B1 (ko) | 2013-01-23 | 2021-04-22 | 알데이라 테라퓨틱스, 아이엔씨. | 독성 알데히드 관련된 질병 및 치료 |
| CN105228989A (zh) | 2013-01-25 | 2016-01-06 | 奥尔德拉医疗公司 | 黄斑变性治疗中的新颖捕获剂 |
| EP3178810A4 (en) * | 2014-08-08 | 2018-07-04 | Kasuma Partners Inc. | Condensed heterocyclic compound |
| EP3189026B1 (en) | 2014-09-02 | 2020-07-22 | The Regents of The University of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| CN104926745A (zh) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途 |
| CN104974103A (zh) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途 |
| EP3337486B1 (en) | 2015-08-21 | 2024-04-03 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| AU2017264697A1 (en) | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| WO2018170476A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| CN108586374B (zh) * | 2018-01-12 | 2021-01-05 | 浙江鼎龙科技有限公司 | 2-苯基苯并噁唑类化合物的制备方法 |
| JP2021533154A (ja) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| CN111467341B (zh) * | 2020-04-24 | 2021-05-11 | 山东师范大学 | 3,4-二甲氧基苯基-苯并[d]恶唑作为肿瘤耐药逆转剂的应用 |
| CN114805112A (zh) * | 2022-05-31 | 2022-07-29 | 常州大学 | 一种pde2抑制剂酰胺类衍生物及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| GB1590587A (en) | 1977-06-28 | 1981-06-03 | Lilly Industries Ltd | Benoxaprofen |
| EP0694535A1 (en) * | 1994-04-29 | 1996-01-31 | Eli Lilly And Company | Non-peptidyl tachykinin receptor antagonists |
| ATE183516T1 (de) | 1995-09-08 | 1999-09-15 | Karobio Ab | Waisen-rezeptor |
| EP0973513A4 (en) | 1996-10-23 | 2003-03-19 | Zymogenetics Inc | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT |
| US5919808A (en) | 1996-10-23 | 1999-07-06 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| US5948776A (en) | 1996-10-23 | 1999-09-07 | Zymogenetic, Inc. | Compositions and methods for treating bone deficit conditions |
| US7157568B1 (en) | 1997-08-05 | 2007-01-02 | American Home Products Corporation | Human estrogen receptor-β |
| DE59905847D1 (de) | 1998-05-05 | 2003-07-10 | Altana Pharma Ag | Benzimidazole und oxazole |
| GB9814620D0 (en) | 1998-07-06 | 1998-09-02 | Karobio Ab | Vasculoprotector |
| AU761647B2 (en) | 1998-07-06 | 2003-06-05 | Altana Pharma Ag | New benzoxazoles with PDE-inhibiting activity |
| WO2000019994A1 (en) | 1998-10-02 | 2000-04-13 | Board Of Trustees Of The University Of Illinois | Estrogen receptor ligands |
| WO2000031112A1 (en) | 1998-11-20 | 2000-06-02 | Akzo Nobel N.V. | Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11 |
| US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| DE69910830T2 (de) | 1998-12-30 | 2004-06-17 | Signal Pharmaceutical, Inc., San Diego | Verbindungen und verfahren zur modulation von estrogen rezeptoren |
| US6358943B1 (en) * | 1999-03-04 | 2002-03-19 | American Home Products Corporation | N-substituted indolines as estrogenic agents |
| AU766648B2 (en) * | 1999-03-17 | 2003-10-23 | Axys Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU3964400A (en) | 1999-04-06 | 2000-10-23 | Akzo Nobel N.V. | Selective estrogenic compounds |
| PT1165184E (pt) | 1999-04-09 | 2004-04-30 | Karobio Ab | Antagonismo do receptor-beta do estrogenio e doencas de ossos |
| US6518301B1 (en) | 1999-04-16 | 2003-02-11 | Astrazeneca Ab | Estrogen receptor-β ligands |
| US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
| GB9913649D0 (en) | 1999-06-11 | 1999-08-11 | Karobio Ab | Estrogen receptor |
| US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| EP1257264B1 (en) | 2000-02-14 | 2011-09-14 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
| AU2002221239A1 (en) * | 2000-12-07 | 2002-06-18 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| EP1345914A1 (en) * | 2000-12-22 | 2003-09-24 | AstraZeneca AB | Therapeutic compounds |
| US6559177B2 (en) | 2001-04-19 | 2003-05-06 | Wyeth | 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| CN101044126A (zh) * | 2004-08-26 | 2007-09-26 | 惠氏公司 | 作为雌激素药物的前药取代的苯并唑化合物 |
-
2002
- 2002-03-12 UA UA20040705301A patent/UA83620C2/ru unknown
- 2002-12-03 PL PL02370771A patent/PL370771A1/xx unknown
- 2002-12-03 CN CNA2008101731403A patent/CN101423500A/zh active Pending
- 2002-12-03 AU AU2002353014A patent/AU2002353014A1/en not_active Abandoned
- 2002-12-03 EP EP07023848A patent/EP1982713A3/en not_active Withdrawn
- 2002-12-03 RU RU2004120283/04A patent/RU2330847C2/ru active
- 2002-12-03 KR KR1020047008680A patent/KR20050044717A/ko active IP Right Grant
- 2002-12-03 WO PCT/US2002/038513 patent/WO2003050095A1/en active Application Filing
- 2002-12-03 CA CA2467517A patent/CA2467517C/en not_active Expired - Fee Related
- 2002-12-03 CN CNB028278186A patent/CN100443477C/zh not_active Expired - Fee Related
- 2002-12-03 MX MXPA04005306A patent/MXPA04005306A/es active IP Right Grant
- 2002-12-03 IL IL16225602A patent/IL162256A0/xx unknown
- 2002-12-03 JP JP2003551120A patent/JP4689960B2/ja not_active Expired - Fee Related
- 2002-12-03 EP EP02789980A patent/EP1451165A1/en not_active Withdrawn
- 2002-12-03 TW TW091135030A patent/TW200304822A/zh unknown
- 2002-12-03 BR BR0214767-0A patent/BR0214767A/pt not_active IP Right Cessation
- 2002-12-03 NZ NZ560878A patent/NZ560878A/en unknown
- 2002-12-03 HU HU0500010A patent/HUP0500010A2/hu unknown
- 2002-12-03 SG SG200603829-3A patent/SG165987A1/en unknown
- 2002-12-04 US US10/309,699 patent/US6794403B2/en not_active Expired - Fee Related
- 2002-12-04 AR ARP020104690A patent/AR037745A1/es unknown
-
2004
- 2004-05-17 US US10/847,100 patent/US7148247B2/en not_active Expired - Fee Related
- 2004-06-01 CO CO04050963A patent/CO5580830A2/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005133A patent/ECSP045133A/es unknown
- 2004-07-01 ZA ZA200405249A patent/ZA200405249B/en unknown
- 2004-07-02 NO NO20042811A patent/NO20042811L/no not_active Application Discontinuation
- 2004-08-19 US US10/921,409 patent/US7129258B2/en not_active Expired - Fee Related
-
2005
- 2005-04-04 IN IN272KO2005 patent/IN2005KO00272A/en unknown
-
2006
- 2006-12-11 US US11/636,947 patent/US7531564B2/en not_active Expired - Fee Related
-
2008
- 2008-02-26 RU RU2008107295/04A patent/RU2008107295A/ru not_active Application Discontinuation
-
2009
- 2009-08-17 AU AU2009210357A patent/AU2009210357A1/en not_active Ceased
-
2010
- 2010-11-15 JP JP2010255175A patent/JP2011052010A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2005KO00272A (hu) | ||
| HUP0201385A2 (hu) | Eljárás a 4"-szubsztituált 9-dezoxo-9a-aza-9a-homoeritromicin-A-származékok előállítására | |
| HUP0104218A2 (hu) | Új szubsztituált fenil-ciklohexil vegyületekből származó észterek | |
| PT915866E (pt) | Processo aperfeicoado para a sintese de esteres protegidos do acido (s)-3,4-di-hidroxibutirico | |
| HUP0001993A2 (hu) | Fungicid hatású (trifluor-metil-alkil)-amino-triazol 0[1,5-a]pirimidin-származékok, előállításuk és alkalmazásuk | |
| PT96897A (pt) | Processo para a preparacao de novos compostos aril-e heteroariletilenicos e de composicoes farmaceuticas que os contem | |
| BG103980A (en) | 4-phenylpiperidine compounds | |
| NZ505220A (en) | Arylpiperazines having activity at the serotonin 1A receptor, processes for their preparation and intermediates | |
| HUP9903836A2 (hu) | Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására | |
| PT1064281E (pt) | Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais | |
| CO4990933A1 (es) | Derivados de indazol triciclicos, su preparacion y su apli- cacion en terapeutica | |
| HUP0203422A2 (hu) | Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| MY123083A (en) | Acyclic nucleoside derivatives | |
| MY118004A (en) | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| HUP0104193A2 (hu) | Javított eljárás új antidiabetikus hatású vegyületek előállítására | |
| AU7349301A (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| CY1107481T1 (el) | Εναντιοεκλεκτικη αλκυλιωση τρικυκλικων ενωσεων | |
| HUP0100740A2 (hu) | Eljárás szubsztituált benzoil-cianid-amidinohidrazonok előállítására | |
| PT1628968E (pt) | Compostos de 4-imidazolin-2-ona | |
| HUP9900679A2 (hu) | Simaizom sejtburjánzást gátló benzimidazolszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| PT982305E (pt) | Novos derivados do indano-1-ol proceso para a sua preparacao e as composicoes farmaceuticas que os contem | |
| HUP0003857A2 (hu) | Eljárás alkoxi-furanon-amin-származékok előállítására, az eljárással kapott vegyületek és a vegyületek alkalmazása | |
| GB9812211D0 (en) | Cinnamoyl distamycin analogous derivatives,process for their preparation,and their use as antitumor agents | |
| DE60307792D1 (de) | Hydroxylierte indirubinderivate | |
| ATE238300T1 (de) | (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine |